Compare VNCE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | CGTX |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 102.9M |
| IPO Year | 2013 | 2021 |
| Metric | VNCE | CGTX |
|---|---|---|
| Price | $6.28 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $5.17 | $3.33 |
| AVG Volume (30 Days) | 358.7K | ★ 2.1M |
| Earning Date | 04-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.45 | 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,007,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.23 | N/A |
| 52 Week Low | $1.19 | $0.52 |
| 52 Week High | $8.20 | $3.83 |
| Indicator | VNCE | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 43.03 |
| Support Level | $2.41 | $0.55 |
| Resistance Level | N/A | $1.23 |
| Average True Range (ATR) | 0.95 | 0.18 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 44.38 | 16.87 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale and Vince Direct-to-consumer. It operates its e-commerce business through its website. Maximum of its revenue generated from Vince Wholesale segment.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).